Skip to content

Clinical study of sarcopenia decoction for the treatment of sarcopenia

Clinical study of sarcopenia decoction for the treatment of sarcopenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091125
Enrollment
Unknown
Registered
2024-10-21
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Experimental group:Sarcopenia decoction
Control group:Calcitriol

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Participants meet the diagnostic criteria for sarcopenia in the Chinese Elderly (2021) established by the Geriatric Branch of the Chinese Medical Association; (1) BIA: ASM/height2(kg/m^2): men=65 years old, gender not limited; (4) Voluntarily participated in this trial and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe malnutrition; 2. People with chronic consumable diseases: advanced neoplastic disease, advanced chronic kidney disease(eGFR< 30), chronic obstructive pulmonary disease, severe diabetes mellitus, other diseases or physiological conditions that can affect muscle mass; 3. Acute mobility loss, such as fractures resulting in reduced mobility, especially hip fractures; 4. Obese including severely obese; 5. Neuromuscular disease, such as Parkinson's disease; 6. Those with known allergies to test drug or allergies to ingredients of the test drug; 7. Patients with Hepatitis B, C and AIDS; 8. Patients with mental diseases; 9. Hearing or vision impairment interfering with communication or daily activities; 10. Cognition impairment person; 11. History of alcohol abuse, substance abuse; 12. According to the judgment of the investigator, there is any subject who has reduced the likelihood of enrollment (such as frailty, etc.), has a tendency to non-compliance during the study, or other lesions that complicate enrollment.

Design outcomes

Primary

MeasureTime frame
Grip strength;

Secondary

MeasureTime frame
SarQoL;Content of muscle ;6-m walking speed;

Countries

China

Contacts

Public ContactYuan Wei'an

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

weian_1980@163.com+86 137 7426 9261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 23, 2026